Primary Investigator:
Madeleine Geraghty, MD

Description:
This study is designed to compare the study medication (pioglitazone) vs. a placebo for prevention of stroke and myocardial infarction (heart attack) in individuals who have recently had either an ischemic stroke or a transient ischemic attack.

Eligibility:

• Ischemic stroke or TIA within prior six months.
• Not on diabetic medication.
• Able to give informed consent and participate in follow-up.
• Insulin resistant (by IRIS blood test).
• Other eligibility criteria may apply. Please contact study coordinator.

Exclusions:

• Age < 45 years
• Stroke or TIA due to structural cardiac lesion, trauma, dissection, or instrumentation
• Class III or IV heart failure
• Advanced liver disease
• Limited life expectancy
• Use of oral steroids or oral contraceptives
• Pregnancy or intended pregnancy
• Other exclusion criteria may apply. Please contact study coordinator.

Study Timeline:
Currently open to enrollment

Study Contact:
Ruthie, RN Ruth.Franks@providence.org

Study Sponsor:
National Institute of Neurological Disorders and Stroke